Five things for pharma marketers to know for Monday morning

Five things for pharma marketers to know

• Moderna’s investigational vaccine for respiratory syncytial virus is 84% effective against the lower respiratory tract illness linked with the virus, according to phase 3 study data.

• Pfizer struck a deal with Nona Biosciences to expand its antibody-drug conjugate portfolio.

• Seattle-based biotech company Immusoft announced that its scientists genetically programmed a patient’s B cells and put them back in his body in an effort to treat disease.

• In a study published in The Lancet, researchers reported on a promising new treatment for the psychiatric disorder that could give patients better options.

• Small-cap biotech Vera Therapeutics’ stock could rise by 70%, according to Wall Street analysts.